Instructions for Credit - There is no fee for this activity. To receive credit for this CME/CE activity, review the accreditation and disclosure information, view the presentation in its entirety, successfully complete the post-activity assessment and evaluation. If you do not achieve a minimum score of 70% on the post-activity assessment, you will be allowed to take it again. This course is accredited for up to 1.0 continuing education credits. Please retain a copy of the certificate for your records.

Target Audience:
Pediatricians, family physicians, physician assistants, nurse practitioners, nurses, and oncology social workers at the intermediate and advanced levels involved in the care of patients with hematologic malignancies.

Learning Objectives:
At the conclusion of this program, participants will be able to:

  • Describe childhood blood cancers, including ALL, AML, and rare lymphomas such as Burkitt.
  • Identify signs and symptoms of childhood blood cancer and diagnostic tests.
  • Assess appropriate referral to a pediatric hematologist-oncologist and patient care during and post-cancer treatment.
  • Explain treatments, including the role of clinical trials, and management of short- and long-term side effects.

Susan R. Rheingold, MD
Medical Director
Oncology Outpatient Clinic
Attending Physician
Cancer Center at Children's Hospital of Philadelphia
Philadelphia, PA

Bradley J. Dyer, MD, FAAP
All Star Pediatrics
Exton, PA

CME/CE Information:
Physician Credit Designation
The "Hematologic Malignancies in Children: Early Diagnosis and Management" program is approved for 1.0 prescribed credit hours by the American Academy of Family Physicians (AAFP). Please complete the evaluation to obtain enduring credit.

Registered Nursing Credit Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under provider number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.

Social Work Credit Designation
The Leukemia & Lymphoma Society (LLS), provider number 1105, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education Program (ACE). Approval Period: 12/10/2017 to 12/10/2020. LLS maintains responsibility for the program. Social workers should contact their regulatory board to determine course approval. Social workers will receive 1.0 CE contact hour.

LLS is recognized by the New York State Education Departments State Board for Social Work as an approved provider of continuing education for licensed social workers #0117. LLS maintains responsibility for the program. Social workers will receive 1.0 clinical CE contact hour for this activity.

All continuing education credits are provided free of charge.

Disclosure of Conflicts of Interest:
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speaker's bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Clinical Directors Network, Inc. and The Leukemia & Lymphoma Society for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Clinical Directors Network, Inc. and The Leukemia & Lymphoma Society, the accredited providers for this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity during the past 12 months.

Faculty Disclosures:
Dr. Dyer has no affiliations to disclose.
Dr. Rheingold has research funding from Pfizer, Inc.

Disclaimer - The information provided in this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Estimated time to complete activity: 1.0 hour
Date of initial release: March 5, 2019
Valid for CME credit through: March 5, 2020
Valid for CE credit through: October 5, 2020